Cinnarizine, pills 25mg 50pcs

Composition

Cinnarizine 25 mg

Pharmacological action

Pharmaceutical group:

blocker of “slow” calcium channels.

Pharmaceutical action:

  Selective BMCC reduces the intake of Ca2+ into cells and reduces their concentration in the plasmolemma depot, reduces the smooth muscle tone of arterioles, and enhances the vasodilating effect of carbon dioxide.

Directly affecting the smooth muscles of blood vessels, it reduces their response to biogenic substances (epinephrine, norepinephrine, dopamine, angiotensin, vasopressin). It has a vasodilating effect (especially in relation to the blood vessels of the brain), without significantly affecting blood pressure.

It shows moderate antihistamine activity, reduces the excitability of the vestibular apparatus, lowers the tone of the sympathetic nervous system.

It is effective in patients with latent cerebral circulatory insufficiency, initial cerebral vascular atherosclerosis, and chronic cerebral vascular diseases with post-stroke focal symptoms.

In patients with peripheral circulatory disorders, it improves blood supply to organs and tissues (including the myocardium), increases post-ischemic vasodilation.

 Increases the elasticity of red blood cell membranes, their ability to deform, and reduces blood viscosity. Increases muscle resistance to hypoxia.

Pharmacokinetics:

TCmax after oral use – 1-3 hours, plasma protein binding-91%. It is completely metabolized in the liver (via dealkylation). T1 / 2-4 hours It is excreted as metabolites: 1/3-kidneys and 2/3 – with feces.

Indications

Chronic cerebrovascular insufficiency (dizziness, tinnitus, headache, memory impairment, decreased concentration). Vestibular disorders (including Meniere’s disease, dizziness, tinnitus, nystagmus, nausea and vomiting of labyrinth origin). Prevention of kinetosis (“road sickness” – sea and air sickness).

Migraine (prevention of seizures).

Peripheral circulatory disorders (intermittent claudication, Raynaud’s disease, diabetic angiopathy, thrombophlebitis, trophic disorders, including trophic and varicose ulcers).

Contraindications

Hypersensitivity, pregnancy, lactation, children under 5 years of age.

With caution. For medicinal products containing lactose (optional): lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome.

Side effects

From the nervous system: drowsiness, increased fatigue, headache, extrapyramidal disorders (tremor of the limbs and increased muscle tone, hypokinesia), depression.

From the digestive system: dryness of the oral mucosa, epigastric pain, dyspepsia, cholestatic jaundice.

From the skin: increased sweating, lichen planus (extremely rare).

Allergic reactions: skin rash.

Other: decreased blood pressure, weight gain, lupus-like syndrome.

Interaction

Increases the effect of ethanol, sedatives, tricyclic antidepressants.

How to take, course of use and dosage

Inside, after eating.

For chronic cerebrovascular insufficiency – 25 mg 3 times a day, in drops-8 drops 3 times a day or 1 capsule (75 mg) 1 time a day.

In case of violation of peripheral blood circulation-50-75 mg 3 times a day.

For the prevention of sea and air sickness-25 mg 30 minutes before the upcoming trip, if necessary, the dose is repeated after 6 hours; for children from 5 years – 1/2 dose for adults.

For vestibular disorders – 25 mg 3 times a day. For children, the dose is reduced by 2 times.

The maximum daily dose should not exceed 225 mg. With high sensitivity to the drug, treatment begins with 1/2 dose, increasing it gradually.

To achieve an optimal therapeutic effect, the drug should be taken continuously, for a long time-from several weeks to several months.

Overdose

Symptoms: vomiting, drowsiness, tremor, excessive lowering of blood pressure, coma.

Treatment: there is no specific antidote, gastric lavage, activated charcoal, symptomatic therapy.

Special instructions

Due to the presence of an antihistamine effect, cinnarizine can affect the result of anti-doping control of athletes (false positive result), as well as neutralize positive reactions during skin diagnostic tests (4 days before the study, treatment should be discontinued).

With prolonged use, it is recommended to conduct a control examination of liver function, kidneys, and peripheral blood picture. Breast-feeding is not recommended for women taking cinnarizine.

Patients with Parkinson’s disease should only be prescribed when the benefits of its use outweigh the possible risk of deterioration.

During the treatment period, care should be taken when driving vehicles and doing other activities. potentially dangerous activities that require increased concentration of attention and speed of psychomotor reactions.

Form of production

Pills.

Active ingredient

Cinnarizine

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

Children as prescribed by a doctor, Adults as prescribed by a doctor, Children over 5 years of age

Indications

Trophic ulcers, Cerebral circulation disorders, Seasickness, Vascular damage in diabetes mellitus, Meniere’s disease, Concussion and other traumatic brain injuries, Stroke consequences, Thrombophlebitis, Migraines, Raynaud ‘s disease